Cart
sales@molnova.com
ELN484228
CAS No. 312-63-0
ELN484228( ELN484228 | ELN-484228 | ELN 484228 )
Catalog No. M18408 CAS No. 312-63-0
ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 31 | In Stock |
|
| 5MG | 50 | In Stock |
|
| 10MG | 68 | In Stock |
|
| 25MG | 143 | In Stock |
|
| 50MG | 219 | In Stock |
|
| 100MG | 385 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameELN484228
-
NoteResearch use only, not for human use.
-
Brief DescriptionELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.
-
DescriptionELN484228 is a cell-permeable alpha-Synuclein Blocker.
-
In Vitro——
-
In Vivo——
-
SynonymsELN484228 | ELN-484228 | ELN 484228
-
PathwayMetabolic Enzyme/Protease
-
TargetFatty Acid Synthase
-
Recptorα-synuclein
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number312-63-0
-
Formula Weight251.28
-
Molecular FormulaC12H10FNO2S
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 50 mg/mL; 198.98 mM
-
SMILESO=S(=O)(Nc1ccc(F)cc1)c2ccccc2
-
Chemical NameN-(4-Fluorophenyl)benzenesulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tóth G, et al. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS One. 2014 Feb 14;9(2):e87133.
molnova catalog
related products
-
Fasnall
Fasnall is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly in combination with carboplatin.
-
trans-C75
trans-C75 is an enantiomer of C75. C75 is an inhibitor of fatty-acid synthase (FASN).
-
UCM05
UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) with efficacy against HER2+ breast cancer xenografts, including cell lines resistant to anti-HER2 drugs .
